FDA calls for investigation into Alzheimer drug approval

Acting commissioner Dr. Janet Woodcock called on the inspector general to investigate Aduhelm’s approval process, asking whether any interactions were inconsistent with FDA policies.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting